..read more

..read more

The PRISMA - Preferred Reporting Items of Systematic reviews and Meta-Analyses statement from 2009 has recently been updated (March 2021) and is an evidence-based guideline with a minimum set of items for reporting in systematic reviews and meta-analyses. It was designed to help systematic reviewers transparently report why the review was done, what the authors did, and what they found. A dedicated global team of methodologists, search specialists, biostatisticians and systematic reviewers have spent the last few years diligently updating the PRISMA statement, including Head of Cochrane Denmar ..read more

..read more

..read more

..read more

..read more

Conflicts of interest in clinical research This dissertation conducted by our researcher Camilla Hansen Nejstgaard studies the impact of conflicts of interest on results, conclusions, and recommendations in different types of clinical research. Clinical research studies, such as randomised trials and systematic reviews, have profound impact on patient care. It is therefore essential, that such studies are trustworthy. Quite often, clinical research is either funded by drug or device companies or written by authors that have ties with individual companies; for example by being on a company’s sp ..read more

Cochrane, together with a range of other civil society organisations, has written to a group of medicines agencies in Europe asking that they take action to ensure trial transparency. Despite an EU legislation requiring that results from clinical trials be published on the EU Clinical Trials Register within 12 months of a study ending, this information has not been shared for almost 30% of applicable trials. The letter calls on the Heads of Medicines Agencies (HMA), a body of national regulators in Europe, to take action to address this serious issue and gives recommendations on how to im ..read more

..read more